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UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION FROM A SIN-
GLE 4/6 MATCHED UNIT IS AN EFFECTIVE THERAPY FOR CHILDREN
WITH MALIGNANT AND NON-MALIGNANT DIAGNOSES: GOOD SUR-
VIVAL, LOW GRAFT FAILURE AND GRAFT-VS-HOST DISEASE IN A SINGLE
CENTER ANALYSIS OF 314 PATIENTS
Prasad, V.K.1, Mendizabal, A.2, Gill, P.1, Parikh, S.H.1, Szabolcs, P.1,
Driscoll, T.A.1, Page, K.1, Wood, S.1, Semmel, D.1, Martin, P.L.1,
Carter, S.2, Kurtzberg, J.1 1Duke University Medical Center, Durham,
NC; 2The EMMES Corporation, Rockville, MD
Background: Despite millions in unrelated registries, many pa-
tients, in particular the minorities can not find a suitable donor. In
contrast, with an inventory of 250,000 almost every patient will
find a 4/6 cord blood unit (CBU). We summarize a large single
center experience utilizing unrelated 4/6 matched CBU in pediatric
patients.
Methods: 314 consecutive patients (median age 6.1 years; range
0.5–21.3 years) undergoing myeloablative transplantation at Duke
between 08/1993 and 11/2007 with a single 4/6 matched (low reso-
lution for HLA-A and –B and high resolution –DRB1) CBU were
studied (median follow-up 6.9 years; range 0.9–15.1 yrs). The pa-
tients (63% male; 27% non-Caucasian; 38% CMV seropositive)
hadmalignant (61%; n5 192; de novo and secondary leukemia, lym-
phoma,MDS, others) and non-malignant (39%; n5 122; metabolic,
immunodeficiency, marrow failure; and hemoglobinopathies) diag-
noses. In total, 51% were mismatched at one and 49% at two class
I HLA loci. The median pre-cryopreserved and reinfused total nu-
cleated cell (TNC) doses were 6.16  107/kg (range, 0.86–38.23)
and 4.80  107/kg (range, 0.54–27.40), respectively. Statistics
included Kaplan-Meier, log-rank, and Cox models.
Results: Cumulative incidence (CINC) of neutrophil engraft-
ment (median 26 days) at 42 days was 77.7%(95%CI, 73.0%-
82.4%) and of platelet engraftment 50K (median 160 days) at 180
days was 52.1%(95%CI, 46.6%-57.6%). Primary graft failure and
autologous recovery occurred in 21 (6.7%) and 10 (3.2%) patients,
respectively. The 100-day CINC of acuteGVHD grades III-IV
was 13.6%(95%CI, 9.7%-17.5%). CINC of chronicGVHD at 1
year was 13.7%(95%CI, 9.8%-17.6%). The probabilities of overall
survival (OS) at 1 year and 3 years were 54.8%(95%CI, 49.1%-
60.1%) and 46.6%(95%CI, 40.9%-52.0%), respectively.
Factors affecting OS in Mutlivariate Analysis
1 year OS Long-term OSHazard
Ratio p-valueHazard
Ratio p-valueFavorable
FactorsTNC
cryopreserved
x 10e7/kg
\ 2.5 1.00 1.00 Cell Dose . 2.5
. 2.5 0.41 0.0003 0.45 0.0005HLA B Mismatch
0 or 1 Mismatch 1.00 1.00 0 or 1 mismatch over
2 mismatch 2.16 0.05 2.02 0.04 2 HLA-B mismatchRecipient Gender
Male 1.00 1.00
Female 1.47 0.03 1.39 0.04 Male RecipientIn multivariate model, 1-year and long-term OS were better in
boys, pre-cryo TNC.2.5  107/kg, and 0 or 1 compared to 2
HLA-B mismatches. The OS in minority and Caucasian patients
was similar. The probability of relapse of malignancy at 5 yrs was
10.1%(95%CI 5.8%-14.4%).
Conclusion: Transplantation using single 4/6 matched CBU is
effective and carries low probabilities of graft failure, acute GVHD
grades III-IV and chronic GVHD in pediatric patients. Outcomes
are similar to those reported with better matched UCB grafts. These
results support the use of 4/6 matching CBU for patients lacking
matched related and unrelated donors improving access for all pa-
tients including the minorities.65
IMMUNE RECONSTITUTION AFTER GENE THERAPY (GTX) FOR ADENO-
SINE DEAMINASE DEFICIENT SEVERE COMBINED IMMUNE DEFICIENCY
(ADA-SCID)
Sokolic, R.1, Podsakoff, G.2, Muul, L.1, Engel, B.2, Jagadeesh, J.1,
Garabedian, E.1, Kesserwan, C.1, Carbonaro, D.3, Choi, Y.C.3,
Shaw, K.3, Hershfield, M.4, Wayne, A.5, Kohn, D.3, Candotti, F.1 1Na-
tional Institutes of Health, Bethesda, MD; 2Children’s Hospital of Phila-
delphia, Philadelphia, PA; 3Childrens Hospital Los Angeles, Los Angeles,
CA; 4Duke University Medical Center, Durham, NC; 5National Insti-
tutes of Health, Bethesda, MD
We report on immune reconstitution in 3 patients (pts) who re-
ceived GT for ADA-SCID. After conditioning with 75 mg/m2
busulfan, pts received 2–5  106 autologous CD341 bone marrow
cells/kg that had been exposed to two retroviral vectors, MND-
ADA and GCsapM-ADA. Chemotherapy was well tolerated,
although in two pts, return of neutrophil counts was delayed.
Post-transplant, indices of immunity improved or normalized. At
18 months after treatment, pt 301N’s absolute lymphocyte counts
(ALC’s) have been up to 600/ml (n.v. 2300–5400/ml). T-cell stim-
ulation index (SI) to phytohemmaglutinin (PHA) and serum immu-
noglobulins and IgG subclass levels have normalized. In addition,
the pt responded normally to tetanus, diphtheria, polio and haemo-
philus vaccines. Recently, he promptly recovered from a gram-neg-
ative central venous catheter infection. Pt 303N is 15 months after
treatment and her ALC have been up to 250/ml. PHA-SI and se-
rum IgA levels have normalized, although the pt remains on IVIG.
Pt 304C has been followed for 9 months. IgA has normalized, but
other indices of immunity remain low. She resumed ADA enzyme
replacement therapy after an episode of pneumonia. Nevertheless,
her mononuclear cell ADA activity and percent corrected cells con-
tinue to increase. In all three pts, ADA activity has risen from less
than 2 units to more than 30 units (n.v. 58–128 units), and toxic
adenosine metabolites have fallen to levels comparable to those
seen in pts who have engrafted after allogeneic hematopoietic cell
transplant. Retroviral vector-marked cells in the peripheral blood
vary from 0.1% (301N) to 15% (303N) of the pts’ circulating
mononuclear cells. A fourth patient was treated on October 2,
2008, and is not yet evaluable. In summary, after treatment with
myelosuppressive chemotherapy and bone marrow GTx, all 3
evaluable pts have shown improvement in laboratory indices of
ADA activity and of immunity. Of the two pts who have been ob-
served for more than a year off of PEG-ADA, one has had no infec-
tions and the other has answered two immunologic challenges as
well as one would expect of a normal child. The results are in line
with those reported by researchers in Italy and UK and indicate
that gene therapy for ADA-SCID can lead to measurable improve-
ment of immune function. While the degree of reconstitution is
only partial when assessed in the laboratory, clinical responses to
immunologic challenges appear to be robust.66
AMBULATORY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) FOR
SEVERE PRIMARY IMMUNODEFICIENCY (PID) IN CHILDREN
Tse, W.T., Guarino, J., Schneiderman, J., Duerst, R., Jacobsohn, D.,
Chaudhury, S., Kletzel, M. Children’s Memorial Hospital, Northwestern
University Feinberg School of Medicine, Chicago, IL
Ambulatory HSCT has many potential benefits, but it is un-
known if it will increase the risk of complications. We studied am-
bulatory HSCT in children with severe PID utilizing a reduced-
intensity conditioning (RIC) regimen. In 2000–2008, 26 children
with PID (SCID (n 5 13), Hyper-IgM (4), Wiskott-Aldrich (2),
XLPD (2), IPEX (2), Omenn (1), NEMO (1), Chediak-Higashi
(1); median age, 0.6 year (range 0.1–17.4)) underwent HSCT after
RIC (fludarabine 30mg/m2/day  6; single-daily dose IV busulfan
 2, with targeted exposure based on area-under-the-curve (AUC)
of a test dose; rabbit ATG 2mg/kg/day  4). Patients received
treatment and care primarily in an ambulatory setting. They
were admitted for in-patient care if they had specific medical or
psychosocial needs. Between transplant day -10 and 1100, the
median number per patient of scheduled clinic visits, acute care
clinic visits and ER visits was 21 (range 0–27), 1 (0–4) and
28 Oral Presentations0 (0–2), respectively. The median number of hospital admissions
per patient was 1 (range 0–4). The reasons for acute care/ER visits
and hospital admissions were tabulated below.
Reasons for acute care/ER visits and hospital
admissionsAcute care/ER visits fever (n523), bacteremia (2), dehydration (6),
bronchiolitis (1), hemolysis (1), gastrointestinal
bleeding (1), pseudotumor cerebri (2), bandemia
(1)
Hospital admissions conditioning (n58), fever with no positive
cultures (14), bacteremia (8), dehydration (4),
bronchiolitis (1), hemolysis (1), gastrointestinal
bleeding (1), pseudotumor cerebri (1), bandemia
(1), CMV (1)In 82.5% of hospital admissions (33/40), the clinical course was
non-complex, with the discharge diagnosis the same as the admission
diagnosis. In 17.5% (7/40), the course was complicated by conditions
that developed while patients were in hospital, including bacteremia
(n5 3), sepsis (3), adenovirus (1), respiratory distress (2), gastrointes-
tinal bleeding (3), and organ failure (2). The median length of the
non-complex and complex hospitalizations was 4 days (range 1–38)
and 50 days (9–80), respectively. On any day, the mean probability
that a patient would be an out-patient was 78.6% (CI 77.0–
80.1%); the probability that the patient would be an in-patient for
a non-complex or complex stay was 8.8% and 12.6%, respectively
(CI 7.3–10.8% and 11.6–13.6%). In an earlier cohort, in which the
busulfan AUC target was 4000–4600 microM-min (n 5 17), 4 pa-
tients had primary graft failure and 3 died from related complica-
tions. In a later cohort with an AUC target of 5000 (n 5 9), no
patients had primary graft failure or death. Survival in these 2 cohorts
was 81.2 and 100%, respectively (median follow-up 32.2 and 10.5
months). All engrafted patients have stable donor chimerism, im-
proved lymphocyte counts, normalized immune function and de-
creased susceptibility to infection. Our data showed that
ambulatory HSCT utilizing a RIC regimen was highly effective in
children with PID.67
IMPACT OF REDUCED INTENSITY CONDITIONING (RIC) IN PEDIATRIC
ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A REPORT FROM THE CIBMTR
Verneris, M.R., Burke, M.J., He, W., Davies, S.M., Eapen, M.,
Wagner, J.E. CIBMTR, Milwaukee, WI
Significant experience now exists with reduced intensity condi-
tion (RIC) regimens prior to allogeneic hematopoietic cell trans-
plantation (HCT) in adults with acute myeloid leukemia and
non-ALL, lymphoid malignancies. Due to concerns that ALL
may require more intensive therapy, there are few reports on the
use of RIC, particularly in children with ALL. Therefore, we eval-
uated the transplant outcomes after RIC and allogeneic HCT in 41
children with ALL. In this retrospective analysis, all patients were
aged 0–18 years with 64% aged 11–18 years; 44% had a Karnofsky
score of\90%; and the disease status at the time of transplant was:
1st complete remission (CR) in 13%, 2nd CR in 41%, and .2nd CR
in 26% and 21% had active disease. The time from diagnosis to
transplant for 1st CR patients was 9 months (8–62 months) and
for $2nd CR patients it was 32 months after 1st CR (range, 6–89
months). 63% were transplanted after 2000. A TBI-based condi-
tioning regimen was used in 33% of patients, while the remainder
(66%) received non-TBI containing regimens consisting of: busul-
fan (34%), cyclophosphamide (15%) and melphalan (17%).
Matched related donors, were available for 37% (50% BM and
50% PBSC), with the remaining (63%) having unrelated donors
(BM in 19%, PBSC in 55% and cord blood in 23%). Most had
GVHD prophylaxis with a calcineurin inhibitor in combination
with either methotrexate (47%) or other agents (41%). The disease
free survival (DFS) and overall survival (OS) at 3 yrs was 31% (95%CI, 16–47%) and 38% (95%CI, 22–54%), respectively. Transplant
related mortality (TRM) at 100 days and 3 years was 18% (95%
confidence interval (CI, 7–30%) and 30% (95% CI, 16–46%).
The incidence of aGVHD (Grade II-IV) at day 1100 was 35%.
At 3 years, cGHVD developed in 23% of patients. Relapse at 3
years was 39% (95% CI, 23–57). This is the largest series describ-
ing outcomes in pediatric patients with ALL undergoing allogeneic
HCT after a RIC. While additional analyses are required, these
data demonstrate that long termDFS andOS can be achieved using
RIC regimens in pediatric patients with ALL.SOLID TUMORS
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ADOPTIVE TRANSFER OF HER2-SPECIFIC T CELLS ERADICATES EXPERI-
MENTAL GLIOBLASTOMA MULTIFORME
Salsman, V.S.1, Kew, Y.2, Powell, S.Z.2, Wels, W.E.3, Grossman, R.2,
Heslop, H.E.1,2, Gottschalk, S.1, Ahmed, N.1 1Baylor College of Medicine,
Houston, TX; 2Weil-Cornell Medical College, Houston, TX; 3Georg-
Speyer-Haus, Frankfurt Am Main, Germany
Background: The intent of this project is to develop an effective
adoptive immunotherapy for glioblastoma multiforme (GBM),
which remains largely incurable with current treatment disciplines.
New therapies are thus needed to improve current outcomes with-
out increasing treatment-related morbidities. Immunotherapies
have the potential to fulfill this need, since they are highly tumor-
specific and cause minimal bystander cell damage. We propose to
use T cells to target the human epidermal growth factor receptor
2 (HER2), a surface antigen, which is overexpressed in GBM.
While the use of HER2 monoclonal antibodies has been limited
by low levels of HER2 expression on GBMs, we show here that
T cells expressing HER2-specific chimeric antigen receptors
(CAR) have potent anti-tumor activity both ex vivo and in animal
models.
Methods:T cells fromGBM patients were retroviraly transduced
to express HER2-specific CAR with a CD28.z signaling domain
(HER2-specific T cells). Primary GBM cells and GBM cell lines
were used to test the function of the generated HER2-specific T
cells. The ex vivo efficacy was determined by their ability 1) to kill
HER2-positive target cells in a cytoxicity assay and 2) to proliferate
and secrete cytokines (IFN-g and IL-2) in response to stimulation
with HER2-positive tumor cells. The in vivo efficacy of the
HER2-specific T cells was tested for the ability to induce tumor re-
gression in an orthotopic murine xenograft model.
Results: Primary HER2-specific T cells killed both HER2-pos-
itive autologous GBM cells and GBM cell lines in cytotoxicity
assays, whereas HER2-negative targets were not killed. Stimulation
of HER2-specific T cells with HER2-positive primary GBM cells
and GBM cell lines resulted in T-cell proliferation and secretion
of IFN-g and IL-2 in aHER2-dependentmanner. Intra-tumoral in-
jection of HER2-specific T cells resulted in eradication of estab-
lished GBM xenografts in an orthotopic murine model. In
contrast, delivery of non-transduced T cells did not change the
tumor growth pattern.
Conclusion: We demonstrate that T-cells expressing HER2-
specific CARs can recognize and kill HER2-positive GBMs. Their
activation results in proliferation and secretion of immunostiumla-
tory cytokines. HER2-specific T cells can effectively eradicate
established GBM xenografts in an orthotopic murine model. These
results indicate that HER2-specific T cells could represent a promis-
ing immunotherapeutic approach for GBM.STEM CELL BIOLOGY
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IDENTIFICATION AND ISOLATION OF THE HEMATOPOIETIC STEM CELL
NICHE INITIATING CELL POPULATION
Kraft, D., Chan, C., Chen, C.-C., Luppen, C., Weissman, I.L. Stanford
University School of Medicine, Stanford, CA
Introduction: Identification and understanding of the cells and
processes that can generate, sustain and influence the HSC niche and
